iData Insights

H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 25, 2016 12:15 IST

H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015 Summary Global Markets Direct s, H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015, provides an overview of the H5N1 Infection (Avian Influenza)s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

H5N1 Infection (Avian Influenza) Overview 10

Therapeutics Development 11

Pipeline Products for H5N1 Infection (Avian Influenza) - Overview 11

Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis 12

H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies 13

H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes 18

H5N1 Infection (Avian Influenza) - Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

H5N1 Infection (Avian Influenza) - Products under Development by Companies 22

H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes 27

H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development 28

Akshaya Bio Inc. 28

Altimmune, Inc. 29

Antigen Express, Inc. 30

Aphios Corporation 31

Aprogen, Inc. 32

BioDiem Ltd 33

BiondVax Pharmaceuticals Ltd. 34

CEL-SCI Corporation 35

Cocrystal Pharma, Inc. 36

CSL Limited 37

Daiichi Sankyo Company, Limited 38

Emergent BioSolutions Inc. 39

Gemmus Pharma Inc. 40

GlaxoSmithKline Plc 41

Green Cross Corporation 42

Hemispherx Biopharma, Inc. 43

iBio, Inc. 44

Immunovaccine, Inc. 45

Inovio Pharmaceuticals, Inc. 46

Johnson & Johnson 47

Kineta, Inc. 48

Medicago Inc. 49

MedImmune, LLC 50

Microbiotix, Inc. 51

Microgen Scientific Industrial Company for Immunobiological Medicines 52

Myelo Therapeutics GmbH 53

NanoBio Corporation 54

Nanotherapeutics, Inc. 55

NanoViricides, Inc. 56

NewLink Genetics Corporation 57

OPKO Health, Inc. 58

PaxVax, Inc. 59

PDS Biotechnology Corporation 60

PeptiDream Inc. 61

Protein Sciences Corporation 62

Shionogi & Co., Ltd. 63

Sirnaomics, Inc. 64

Takeda Pharmaceutical Company Limited 65

TechnoVax, Inc. 66

Theraclone Sciences, Inc. 67

Vaxine Pty Ltd 68

VaxInnate Corporation 69

H5N1 Infection (Avian Influenza) - Therapeutics Assessment 70

Assessment by Monotherapy Products 70

Assessment by Combination Products 71

Assessment by Target 72

Assessment by Mechanism of Action 74

Assessment by Route of Administration 76

Assessment by Molecule Type 78

Drug Profiles 80

A-06 - Drug Profile 80

AE-443p - Drug Profile 81

Alferon LDO - Drug Profile 83

AP-302 - Drug Profile 84

APP-0205 - Drug Profile 85

APP-309 - Drug Profile 86

AT-301 - Drug Profile 87

CEL-1000 - Drug Profile 88

DP-C005 - Drug Profile 90

FBF-001 - Drug Profile 91

FDX-000 - Drug Profile 92

Gamma-Flu - Drug Profile 93

GP-1001 - Drug Profile 94

GP-1002 - Drug Profile 95

GP-1681 - Drug Profile 96

GREFLU/VIE - Drug Profile 98

HAI-05 - Drug Profile 99

iHA-24 - Drug Profile 100

Influ-nRNA - Drug Profile 101

influenza (strain H5N1, H1N1) vaccine - Drug Profile 102

influenza [strain A/H5N1] vaccine - Drug Profile 103

influenza [strain A/H5N1] vaccine - Drug Profile 104

influenza [strain H5N1, H7N2, H9N2] virus like particle vaccine - Drug Profile 105

influenza [strain H5N1] (split virion) vaccine - Drug Profile 106

influenza [strain H5N1] vaccine - Drug Profile 107

influenza [strain H5N1] vaccine - Drug Profile 108

influenza [strain H5N1] vaccine - Drug Profile 109

influenza [strain H5N1] vaccine - Drug Profile 110

influenza [strain H5N1] vaccine - Drug Profile 112

influenza [strain H5N1] vaccine - Drug Profile 113

influenza [strain H5N1] vaccine - Drug Profile 114

influenza [strain H5N1] vaccine - Drug Profile 115

influenza [strain H5N1] vaccine - Drug Profile 116

influenza [strain H5N1] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 117

influenza [strain H5N1] virus like particles vaccine - Drug Profile 119

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 121

influenza A vaccine - Drug Profile 122

influenza vaccine - Drug Profile 123

influenza vaccine - Drug Profile 124

influenza virus like particle vaccine - Drug Profile 126

Innate Immune Adjuvants - Drug Profile 127

INO-3510 - Drug Profile 128

IPS-07 series - Drug Profile 129

JNJ-872 - Drug Profile 130

KD-295 - Drug Profile 132

KIB-PCI - Drug Profile 133

M-001 - Drug Profile 134

MBX-2329 - Drug Profile 137

MBX-2546 - Drug Profile 139

MEDI-550 - Drug Profile 140

MG-1109 - Drug Profile 142

Monoclonal Antibodies to Inhibit H5 HA and H7 HA for Avian Infection - Drug Profile 144

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile 145

MVAH-5HA - Drug Profile 146

Myelo-001 - Drug Profile 147

NVINF-1 - Drug Profile 148

NVINF-2 - Drug Profile 150

OrniFlu - Drug Profile 151

PanBlok - Drug Profile 152

PDS-0102 - Drug Profile 154

PNSIA-28 - Drug Profile 155

PNSIA-49 - Drug Profile 156

PXVX-0103 - Drug Profile 157

rintatolimod - Drug Profile 159

S-033188 - Drug Profile 161

Small Molecules to Activate Sirtuin for Influenza - Drug Profile 162

Small Molecules to Inhibit Endonuclease for Flu - Drug Profile 163

STP-702 - Drug Profile 164

Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 165

TCN-032 - Drug Profile 166

TVX-003 - Drug Profile 168

VAX-161 - Drug Profile 169

VGX-3400X - Drug Profile 170

VH-244 - Drug Profile 172

H5N1 Infection (Avian Influenza) - Recent Pipeline Updates 174

H5N1 Infection (Avian Influenza) - Dormant Projects 200

H5N1 Infection (Avian Influenza) - Discontinued Products 205

H5N1 Infection (Avian Influenza) - Product Development Milestones 206

Featured News & Press Releases 206

Appendix 213

Methodology 213

Coverage 213

Secondary Research 213

Primary Research 213

Expert Panel Validation 213

Contact Us 213

Disclaimer 214"

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects